Human hybridomas, precursors and products
US4668629A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 9, 1984 |
| Grant date | May 26, 1987 |
| Priority date | — |
| Expiry date | Apr 9, 2004 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human monoclonal antibody compositions, human-human monoclonal hybridoma cells, human myeloma cells, human antibody genes and their uses. Human myeloma cells are developed for fusing with immunized lymphoid cells to provide stable human-human hybridoma strains producing complete monoclonal antibodies for a predefined antigen. From a myeloma cell line, rapidly growing 8-azaguanine resistant HAT sensitive cells are selected. The selected myeloma cells are crossed with immunized lymphoid cells and the resulting cell mixture grown under controlled selective conditions. After expansion of the desired hybridoma cells, the monoclonal antibodies may be harvested. The hybridomas serve as a source for messenger RNA for light and heavy chains which may be used for production of light and heavy chain immunoglobulin proteins through hybrid DNA techniques.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.